Omeros Corp
NASDAQ:OMER
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Omeros Corp
Cash from Operating Activities
Omeros Corp
Cash from Operating Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Omeros Corp
NASDAQ:OMER
|
Cash from Operating Activities
-$116.1m
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-6%
|
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Cash from Operating Activities
$24.5B
|
CAGR 3-Years
6%
|
CAGR 5-Years
0%
|
CAGR 10-Years
3%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Cash from Operating Activities
$14.2B
|
CAGR 3-Years
3%
|
CAGR 5-Years
0%
|
CAGR 10-Years
21%
|
|
|
|
Pfizer Inc
NYSE:PFE
|
Cash from Operating Activities
$11.7B
|
CAGR 3-Years
-26%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-2%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Cash from Operating Activities
$16.5B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
10%
|
CAGR 10-Years
3%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Cash from Operating Activities
$16.8B
|
CAGR 3-Years
30%
|
CAGR 5-Years
21%
|
CAGR 10-Years
19%
|
|
Omeros Corp
Glance View
Omeros Corp. operates as a biopharmaceutical company. The company is headquartered in Seattle, Washington and currently employs 213 full-time employees. The company went IPO on 2009-10-08. The firm is focused on discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting inflammation, immunologic diseases and cancers. The Company’s lead MASP-2 inhibitor narsoplimab targets the lectin pathway of complement and is the subject of a biologics license application for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. Narsoplimab is also in multiple late-stage clinical development programs focused on other complement-mediated disorders, including IgA nephropathy, atypical hemolytic uremic syndrome and coronavirus (COVID-19). OMS906, the Company’s inhibitor of MASP-3, the alternative pathway of complement, is in a Phase 1 clinical trial.
See Also
What is Omeros Corp's Cash from Operating Activities?
Cash from Operating Activities
-116.1m
USD
Based on the financial report for Dec 31, 2025, Omeros Corp's Cash from Operating Activities amounts to -116.1m USD.
What is Omeros Corp's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 10Y
-6%
Over the last year, the Cash from Operating Activities growth was 22%. The average annual Cash from Operating Activities growth rates for Omeros Corp have been -10% over the past three years , -3% over the past five years , and -6% over the past ten years .
